MAPT and Alzheimer disease: Our study aims to determine whether oxidative stress and inflammation-related metabolites in the prostaglandin and isoprostane pathway in CSF and plasma, are associated with Aβ-42, p-tau and t-tau levels in CSF during the prodromal phase of AD.